High-Throughput Screening for Drug Combinations.

The identification of drug combinations as alternatives to single-agent therapeutics has traditionally been a slow, largely manual process. In the last 10 years, high-throughput screening platforms have been developed that enable routine screening of thousands of drug pairs in an in vitro setting. In this chapter, we describe the workflow involved in screening a single agent versus a library of mechanistically annotated, investigation, and approved drugs using a full dose-response matrix scheme using viability as the readout. We provide details of the automation required to run the screen and the informatics required to process data from screening robot and subsequent analysis and visualization of the datasets.

[1]  Michael Schindler,et al.  Theory of synergistic effects: Hill-type response surfaces as ‘null-interaction’ models for mixtures , 2017, Theoretical Biology and Medical Modelling.

[2]  Sam Michael,et al.  mQC: A Heuristic Quality-Control Metric for High-Throughput Drug Combination Screening , 2016, Scientific Reports.

[3]  J. Lehár,et al.  Systematic discovery of multicomponent therapeutics , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Xiaohua Douglas Zhang.  A pair of new statistical parameters for quality control in RNA interference high-throughput screening assays. , 2007, Genomics.

[5]  Ruili Huang,et al.  The Tox21 robotic platform for the assessment of environmental chemicals--from vision to reality. , 2013, Drug discovery today.

[6]  Damien Y. Duveau,et al.  Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma , 2017, Clinical Cancer Research.

[7]  Sam Michael,et al.  Compound Management for Quantitative High-Throughput Screening , 2008, JALA.

[8]  Robert Nadon,et al.  Statistical practice in high-throughput screening data analysis , 2006, Nature Biotechnology.

[9]  J. Lehár,et al.  Synergistic drug combinations improve therapeutic selectivity , 2009, Nature Biotechnology.

[10]  P. Sorger,et al.  Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs , 2016, Nature Methods.

[11]  Michael Costanzo,et al.  Systematic exploration of synergistic drug pairs , 2011, Molecular systems biology.

[12]  Yang Xie,et al.  A community computational challenge to predict the activity of pairs of compounds Citation , 2015 .